You are here

Zenobia Therapeutics, Inc.

Company Information
Address
3550 General Atomics Ct Building 2 Room 435
SAN DIEGO, CA 92121-1122
United States


http://zenobiatherapeutics.com

Information

UEI: LPJTA7TN4LS8

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: Yes



Award Charts




Award Listing

  1. SBIR Phase II: A web-application that enables hands-on biotech laboratory education for students regardless of socioeconomic status

    Amount: $1,000,000.00

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is equitable access to a quality science education regardless of socioeconomic status or geog ...

    SBIRPhase II2023National Science Foundation
  2. SBIR Phase I: XplorStem(TM): A smartphone/tablet application that enables hands-on biotech laboratory education for all students regardless of socioeconomic status

    Amount: $225,000.00

    This SBIR Phase I project is focused on developing a mobile biotech laboratory for high schools. Education in biotech is limited from a practical point of view to schools with the funds to purchase ex ...

    SBIRPhase I2019National Science Foundation
  3. I Corp Program fro HOT ROXS An integrated platform for identifying activators of "non druggable" targets

    Amount: $397,750.00

    DESCRIPTION provided by applicant Enzyme activators are significantly underrepresented as therapeutic agents versus enzyme inhibitors There are only about a dozen examples of activator discovery i ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  4. Discovery of inhibitors of the lipopolysaccharide synthesis pathway enzymes LpxA

    Amount: $456,299.00

    DESCRIPTION (provided by applicant): Bacterial resistance to antibiotics has been an evolving problem since the dawn of the antibiotics era, requiring consistent scientific advances over the years in ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  5. Discovery of inhibitors of ALK for the treatment of cancer

    Amount: $328,829.00

    DESCRIPTION (provided by applicant): Our aim is to discover novel safety assessment candidates (pre-clinical compounds) for the treatment of cancer by targeting the receptor tyrosine kinase (RTK), ana ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government